Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (“Algernon” or the “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical development company, announces that effective November 24, 2021, the Company will consolidate its Class A common shares (the “Common Shares”) on a one-hundred (100) to one (1) basis (the “Consolidation”). Read More